CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

BACKGROUND: Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T cell activation despite described T cell dysfunction in chronic lymphocytic leukemia (CLL), and are able to effectively target high-risk or venetoclax-resistant samples, is currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Martens, Anne W J, Janssen, Susanne R, Derks, Ingrid A M, Adams III, Homer C, Izhak, Liat, van Kampen, Roel, Tonino, Sanne H, Eldering, Eric, van der Windt, Gerritje J W, Kater, Arnon P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319711/
https://www.ncbi.nlm.nih.gov/pubmed/32581054
http://dx.doi.org/10.1136/jitc-2019-000218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319711/
https://www.ncbi.nlm.nih.gov/pubmed/32581054
http://dx.doi.org/10.1136/jitc-2019-000218

Ejemplares similares